The following represents disclosure information provided by authors of this abstract. The program committee has reviewed all presenting author disclosure reports, identified potential conflicts of interest, and implemented strategies to manage those areas of conflict, where appropriate. All relationships are considered compensated. Relationships are self-held unless otherwise noted. I = Immediate Family Member, Inst = My Institution
 
Open Payments is a public database containing information reported by companies about payments made to US-licensed physicians (Open Payments)
Impact of UGT1A1 genotype on overall survival in Japanese advanced colorectal cancer patients treated by irinotecan-based regimens.
 
Wataru Ichikawa
Honoraria - Chugai Pharma; Daiichi Sankyo; Merck Serono; Nippon Kayaku; Sawai Pharmaceutical Co; Taiho Pharmaceutical; Takeda
Consulting or Advisory Role - Daiichi Sankyo; Merck Serono; Ono Pharmaceutical; Zeria Pharmaceutical
Research Funding - Eisai; Taiho Pharmaceutical; Takeda
Travel, Accommodations, Expenses - Daiichi Sankyo
 
Keisuke Uehara
No Relationships to Disclose
 
Keisuke Minamimura
Research Funding - Daiichi Sankyo (Inst)
 
Chihiro Tanaka
No Relationships to Disclose
 
Yasumasa Takii
Honoraria - Chugai Pharma; Daiichi Sankyo; Taiho Pharmaceutical
Research Funding - Daiichi Sankyo (Inst)
 
Hideaki Miyauchi
Research Funding - Daiichi Sankyo (Inst)
 
Sotaro Sadahiro
Honoraria - Daiichi Sankyo
Research Funding - Daiichi Sankyo (Inst)
 
Katsunori Shinozaki
Honoraria - AstraZeneca; Chugai Pharma; Daiichi Sankyo; GlaxoSmithKline K.K.; Merck Serono; Novartis; Ono Pharmaceutical; Otsuka; Taiho Pharmaceutical; Yakult Honsha
 
Kanehisa Fukumoto
No Relationships to Disclose
 
Toshio Otsuji
Research Funding - Daiichi Sankyo (Inst)
 
Takeshi Kambara
Research Funding - Daiichi Sankyo (Inst)
 
Satoshi Morita
Honoraria - Daiichi Sankyo
Consulting or Advisory Role - Daiichi Sankyo
 
Yuichi Ando
Honoraria - ARKRAY; ASKA Pharmaceutical; AstraZeneca Japan; Bayer; Benesse Style Care; Boehringer Ingelheim; Bristol-Myers Squibb; Chugai Pharma; Eisai; GlaxoSmithKline; Hisamitsu Pharmaceutical; Janssen; Kowa; Kyowa Hakko Kirin; Lilly Japan; Meiji Seika Kaisha; Mochida Pharmaceutical Co. Ltd.; Nippon Kayaku; Novartis; Ono Pharmaceutical; Taiho Pharmaceutical; Takeda; TERUMO; Yakult Honsha
Consulting or Advisory Role - Boehringer Ingelheim; Daiichi Sankyo; GlaxoSmithKline; Kowa; Novartis; Ono Pharmaceutical; Parexel
Research Funding - Chugai Pharma (Inst); Eisai (Inst); Hisamitsu Pharmaceutical (Inst); Kyowa Hakko Kirin (Inst); Merck Serono (Inst); Mitsubishi Tanabe Pharma (Inst); Mochida Pharmaceutical Co. Ltd. (Inst); Nippon Kayaku (Inst); Takeda (Inst); Torii Pharmaceutical (Inst); Yakult Honsha (Inst)
 
Miyuki Arai
Employment - Daiichi Sankyo
 
Masahiro Sugihara
Employment - Daiichi Sankyo
Stock and Other Ownership Interests - Eisai
 
Toru Sugiyama
Honoraria - Daiichi Sankyo
Consulting or Advisory Role - Daiichi Sankyo
 
Yasuo Ohashi
Leadership - Statcom
Stock and Other Ownership Interests - Statcom
Consulting or Advisory Role - Daiichi Sankyo
 
Yuh Sakata
Honoraria - Daiichi Sankyo; Taiho Pharmaceutical; Yakult Honsha
Consulting or Advisory Role - Daiichi Sankyo; Otsuka; Taiho Pharmaceutical